OPTN OptiNose Accounting Capitalization

Public company logo of OptiNose (OPTN)

The share price retrospective for OptiNose, Inc. (OPTN) on the GURU.Markets platform, reaching -0.06, serves as an indicator of the strategy to implement innovative nasal treatments for migraines and sinusitis through retail partnerships. The business relies on US-based capacities and the unique Exhalation Delivery System method, ensuring the steady production of high-tech drug delivery systems.

OPTN OptiNose Corp Book Capitalization (07/04/2022 - 05/31/2025)

Metric breakdowns and analytics for OptiNose (OPTN)

- price and consensus price forecast:
Price OptiNose Corp|OPTN - Price Target Chart
- market capitalization data:
Market Capitalization OptiNose Inc|OPTN - Total Company Value
- book capitalization data:
Share Book Value OptiNose|OPTN - Book Capitalization|Market Value to Book Value optinose.com|OPTN - Company Total Assets
- debt and liquidity data:
Total Debt to Capital OptiNose, Inc.|OPTN - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital OptiNose Inc|OPTN - Company Debts|Debt to Book Value OptiNose Inc
Fundamental valuation:OPTN - OptiNose Corp
Flagship merchandise of OptiNose Inc

Book value capitalization reflects the fundamental value of net assets minus all debt obligations, serving as a measure of the business's real financial stability. By analyzing the book value of equity trend, an investor can see how sales of nasal systems generate sufficient working capital to fully cover the operating expenses and current liabilities of OptiNose, Inc. (OPTN).

Competitor analysis for OptiNose, Inc.

HLN: Total Net Assets|Company Book Value Kenvue Inc.|VRNA (veronapharma.com) - Accounting Capitalization|Company Book Value Jyong Biotech MENS|Net Asset Value Ligand Pharmaceuticals Incorporated|Amneal Pharmaceuticals Inc (AMRX) - Book Capitalization|Accounting Value of Company Perrigo Corp (PRGO)|Book Capitalization ALVO (Alvotech)|liquidia.com - Book Capitalization|Company Book Value Galapagos (GLPG)|ANIP: Accounting Value of Company|MNKD (MannKind Corp.) - Company Book Value|Amphastar Corp (AMPH) - Company Net Assets|PCRX (Pacira BioSciences) - Book Capitalization|Book Capitalization ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Company Net Assets|Accounting Value of Company AQST (Aquestive Therapeutics Inc)|SCPH: Company Book Value|TECX - Total Stockholders' Equity|Company Net Assets Tonix Pharmaceuticals TNXP|SXTC - Total Net Assets|Book Capitalization eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Accounting Value of Company|Book Capitalization EXOZ (Invizyne Technologies, Inc.)|Total Stockholders' Equity ORMP|Entera Bio Ltd. (ENTX) - Company Book Value|Accounting Value of Company HYFT (ipatherapeutics.com)|ABVC: Company Book Value|Cumberland Pharmaceuticals Inc - Total Stockholders' Equity|Company Book Value Quantum BioPharma Limited|FibroGen Corporation (FGEN) - Net Asset Value|TELO - Company Net Assets|Rani Therapeutics Holdings, Inc. (RANI) - Total Net Assets|SNYR: Book Capitalization|Book Valuation of Business RLYB|Company Book Value Lexaria Bioscience LEXX|Accounting Capitalization PULM (Pulmatrix Corporation)|PTHL: Company Book Value|Aptorum Group Ltd - Total Stockholders' Equity|Company Book Value LYRA (Lyra Therapeutics)|IBO - Book Valuation of Business|Book Capitalization TNFA|Total Stockholders' Equity cbdMD|PRFX - Company Net Assets|Accounting Value of Company Auris Medical|LIPO (Lipella Pharmaceuticals, Inc.) - Book Capitalization|Book Valuation of Business PIRS (Pieris Pharmaceuticals Inc)|PROC - Company Book Value|Accounting Capitalization Petros Pharma PTPI|QLI: Book Capitalization|acelyrin.com (SLRN) - Company Net Assets|TFF Pharmaceuticals, Inc. - Company Net Assets